Abstract
BackgroundBiological treatment (BT) has changed the evolution of rheumatic diseases. A way to evaluate the effectiveness of BTs is considering therapeutic survival as an effectiveness subrogate markerObjectivesTo describe BT use;...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
